A multi-center, phase Ib study of subcutaneous administration of isatuximab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma

Ver/Abrir
Identificadores
URI: https://hdl.handle.net/10902/34533
ISSN: 0390-6078
ISSN: 1592-8721
Compartir
Estadísticas
Ver Estadísticas
Google Scholar
Registro completo
Mostrar el registro completo DC
Autoría
Quach, Hang; Parmar, Gurdeep; Ocio San Miguel, Enrique MaríaAutoridad Unican; Prince, H. Miles; Oriol, Albert; Crowther, Helen; Tsukada, Nobuhiro; Bories, Pierre; Madan, Sumit; Nathwani, Nitya; Sunami, Kazutaka; Semiond, Dorothee; Yu, Disa; Cordero, Paul; Macé, Sandrine; Suzan, Florence; Moreau, Philippe
Fecha
2024
Derechos
© Ferrata Storti Foundation. Hang Quach es al., 2024, A multi-center, phase Ib study of subcutaneous administration of isatuximab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple mieloma. Obtained from the Haematologica Journal website http://www.haematologica.org. Creative Commons Reconocimiento-NoComercial.
Publicado en
Haematologica, 2024
Editorial
Ferrata Storti Foundation
Enlace a la publicación
Colecciones a las que pertenece
© Ferrata Storti Foundation. Hang Quach es al., 2024, A multi-center, phase Ib study of subcutaneous administration of isatuximab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple mieloma. Obtained from the Haematologica Journal website http://www.haematologica.org. Creative Commons Reconocimiento-NoComercial.Excepto si se señala otra cosa, la licencia del ítem se describe como © Ferrata Storti Foundation. Hang Quach es al., 2024, A multi-center, phase Ib study of subcutaneous administration of isatuximab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple mieloma. Obtained from the Haematologica Journal website http://www.haematologica.org. Creative Commons Reconocimiento-NoComercial.